BPTES

• Description :

  BPTES is an allosteric and selective glutaminase inhibitor with an IC50 of 0.16 μM.

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319, H335

• Target :

  Glutaminase

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/BPTES.html

• Purity :

  98.75

• Solubility :

  DMSO : 25 mg/mL (ultrasonic)

• Smiles :

  O=C(NC1=NN=C(CCSCCC2=NN=C(NC(CC3=CC=CC=C3)=O)S2)S1)CC4=CC=CC=C4

• Molecular Formula :

  C24H24N6O2S3

• Molecular Weight :

  524.68

• Precautions :

  H315, H319, H335

• References & Citations :

  [1]Elgogary A, et al. Combination therapy with BPTES nanoparticles and targets the metabolic heterogeneity of pancreatic cancer. Proc Natl Acad Sci U S A. 2016 Sep 6;113 (36) :E5328-36.|[2]Meghan J. Seltzer, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010 Nov 15; 70 (22) : 8981-8987.|[3]Lee JS, et al. Glutaminase 1 inhibition reduces thymidine synthesis in NSCLC. Biochem Biophys Res Commun. 2016 Aug 26;477 (3) :374-82|[4]Lee JS, et al. Dual targeting of glutaminase 1 and thymidylate synthase elicits death synergistically in NSCLC. Cell Death Dis. 2016 Dec 8;7 (12) :e2511.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [314045-39-1]